Email kami sekarang untuk melakukan pemesanan Anda dengan dukungan 1-on-1. Stok terbatas! Kami menerima Zelle, CashApp, Venmo, transfer bank, dan kripto.
Tirzepatideadalah turunan sintetis dari polipeptida penghambatan lambung (GIP) yang memiliki fungsionalitas peptida-1 (GLP-1) seperti glukagon simultan juga. Kombinasi ini memungkinkan tirzepatida untuk menurunkan kadar glukosa darah, meningkatkan sensitivitas insulin, meningkatkan perasaan kenyang, dan mempercepat penurunan berat badan. Tirzepatide dikembangkan untuk melawan diabetes tipe 2, tetapi juga telah terbukti melindungi sistem kardiovaskular dan bertindak sebagai agen penurunan berat badan yang kuat.
Bebas (1) 30 mL air bakteriostatik dengan pesanan yang memenuhi syarat$ 500 USD.
(Tidak termasuk produk kapsul, peptida kosmetik, kode promo dan pengiriman)
Tirzepatideadalah turunan sintetis dari polipeptida penghambatan lambung (GIP) yang memiliki fungsionalitas peptida-1 (GLP-1) seperti glukagon simultan juga. Kombinasi ini memungkinkan tirzepatida untuk menurunkan kadar glukosa darah, meningkatkan sensitivitas insulin, meningkatkan perasaan kenyang, dan mempercepat penurunan berat badan. Tirzepatide dikembangkan untuk melawan diabetes tipe 2, tetapi juga telah terbukti melindungi sistem kardiovaskular dan bertindak sebagai agen penurunan berat badan yang kuat.
Penggunaan Produk:Produk ini dimaksudkan sebagai bahan kimia penelitian saja.Penunjukan ini memungkinkan penggunaan bahan kimia penelitian secara ketat hanya untuk pengujian in vitro dan eksperimen laboratorium saja. Semua informasi produk yang tersedia di situs web ini hanya untuk tujuan pendidikan. Pengenalan tubuh dalam bentuk apa pun ke dalam manusia atau hewan dilarang secara ketat oleh hukum. Produk ini hanya boleh ditangani oleh profesional berlisensi dan berkualifikasi. Produk ini bukan obat, makanan, atau kosmetik dan mungkin tidak disalahgunakan, disalahgunakan, atau disesatkan sebagai obat, makanan atau kosmetik.
Tirzepatide
Tirzepatide adalah analog sintetis dari polipeptida penghambatan lambung (GIP) yang dikembangkan karena kemampuannya merangsang pelepasan insulin dan dengan demikian mengatasi diabetes tipe 2 dan penyakit hati berlemak non-alkohol. Terbuat dari 39 asam amino, tirzepatida yang relatif besar merangsang pelepasan insulin dari pankreas dengan mengikat reseptor GIP dan GLP-1 (peptida seperti glukagon-1). Mengambil alih periode waktu yang lebih lama, Tirzepatide meningkatkan kadar adiponektin sebanyak 26% juga [1]. Penelitian menunjukkan bahwa Tirzepatide mengurangi perasaan lapar, menurunkan kadar insulin, dan meningkatkan sensitivitas insulin. Secara keseluruhan, efek ini menyebabkan penurunan berat badan yang signifikan 11 kg (25 lbs), meningkatkan toleransi glukosa, mengurangi jaringan lemak (adiposa), dan mengurangi risiko kardiovaskular.
Struktur Tirzepatide
Urutan asam amino:Ye-asib-gtftsdysi-alib-ldkiaq(Asam lemak C20)AFVQWLIAGGPSSGAPPPSCatatan:AIB adalah asam amino non-kode (non-proteinogenik)-h2H-C (ch3)2–CoohFormula Molekul:C225H348N48HAI68Berat molekul:4813.527 g/molPubchem CID:156588324
Nomor CAS:2023788-19-2Sinonim:P1206, LY3298176Sumber:Pubch
Apa yang dilakukan Tirzepatide?
Simply put, Tirzepatide increases the release of insulin from the pancreas resulting in improved glucose control. Research shows that, in individuals with Type 2 diabetes, Tirzepatide decreases hemoglobin A1c (HbA1c) levels by 2.4% after six months. The peptide also appears to aid in weight loss, showing a dose-dependent relationship and helping individuals lose as much as 11 kg (25 lbs) over six months[1], [2].
It isn’t just that Tirzepatide increases insulin release though. Research suggests that the peptide actually improves the function of pancreatic beta cells, the cells that make and release insulin. Studies suggest that Tirzepatide may actually make beta cells more effective at processing insulin, which leads not just to increases in insulin levels in the bloodstream, but decreased stress on the beta cells themselves. This may, in turn, help to slow the progressive nature of type 2 diabetes.
Research shows that Tirzepatide doesn’t just increase insulin levels at random though. It appears to do so only in response to increased blood glucose levels. During fasting, Tirzepatide actually decreases insulin levels and thus helps to increase insulin sensitivity over time. It also decreases fasting levels of glucagon, which are thought to exacerbate hyperglycemia by interfering with hepatic glucose metabolism. Overall, these changes are a big part of the reason Tirzepatide has a profound effect on glucose and, ultimately, HbA1c levels[3].
Bagaimana cara kerja Tirzepatide?
Tirzepatide is a dual agonist of the gastric inhibitory polypeptide receptor and the glucagon-like peptide-1 receptor. Action at these receptors appears to have synergistic effects that make Tirzepatide more effective than strict GLP-1 agonists that are already approved for the treatment of type 2 diabetes. The affinity of Tirzepatide for the GIP receptor is greater than its affinity for the GLP-1 receptor.
Gastric inhibitory polypeptide, which is also referred to as the glucose-dependent insulinotropic polypeptide, is synthesized naturally in the small intestine. This polypeptide binds to the GIP receptor to inhibit gastric acid secretion and gastrin release while stimulating insulin release. The latter is the primary function of GIP-R and is the primary reason that insulin levels increase following a meal.
Glucagon-like peptide-1 receptors are found on beta cells as well as in neurons in the brain. Like GIP-R, stimulation of GLP-1R stimulates the release of insulin. Natural agonists include glucagon and GLP1, but it has also been shown to bind nearly a dozen synthetic agonists including dulaglutide, lithium, and oxyntomodulin. Activation of GLP-1R increases both insulin synthesis and insulin release, factors that have made it a desirable target in drug development. In the brain, GLP-1R stimulation lowers appetite.
Interestingly, stimulation of GLP-1R appears to increase beta cell density in the pancreas. GLP-1R stimulation increases expression of the anti-apoptotic bcl-2 gene while reducing expression of pro-apoptotic bax and caspase-3 genes. This leads to enhanced beta cell survival and, ultimately, to increased levels of insulin[4].
The combination of GIPR and GLP-1R activity is what gives Tirzepatide an edge over strict GLP-1R agonists. Research shows that Tirzepatide acts identically to GIP at the GIPR, but favors cAMP production over β-arrestin recruitment when acting at the GLP-1R. These details may seem esoteric to some extent, but this difference in activity from endogenous GLP-1 appears to cause GLP-1R activation without increasing physiological internalization of the receptor. The net result is enhanced GLP-1R activity with Tarazepide compared to both endogenous GLP-1 as well as other synthetic GLP-1R agonists[5]. These slight alterations mean that Tirzepatide drastically enhances insulin secretion, promotes feelings of satiety, and reduces inflammation in adipose tissue. These combined effects make it a highly efficacious anti-diabetes peptide.
Finally, Tirzepatide appears to alter adiponectin levels, raising overall levels of the fat-burning peptide. Increased levels of adiponectin reduce fat cell differentiation and increase energy expenditure by making mitochondria more inefficient. A low level of this peptide hormone has been implicated in diseases such as type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease[6]. It is worth noting that elevated adiponectin levels elevate insulin sensitivity, so it would appear that Tirzepatide modulates insulin sensitivity via several mechanisms.
Tirzepatide dan kelaparan
Research shows that Tirzepatide delays gastric emptying during the earliest phases of its administration but that the effect diminishes over time as a result of tachyphylaxis[7]. These effects are similar to those seen with pure GLP-1R agonists, indicating that this action of Tirzepatide is almost completely controlled by its GLP-1 activity and not at all by its GIP activity.
It appears that the effects of Tirzepatide on gastric emptying can be prolonged if the peptide is taken at a low dose for four weeks and then the dose is escalated. This also helps to mitigate side effects caused by the peptide and creates a veritable win-win for patients. Delayed gastric emptying can help to increase feelings of satiety and reduce hunger as well as food cravings. Combined with the effects Tirzepatide has on glucose levels, this can actually help to alter eating patterns over the long term.
Tirzepatide dan berat
As noted above, Tirzepatide use is associated with substantial weight loss over a six-month time interval. A comparison of Tirzepatide to other GLP-1 analogues, like degludoc, indicates a striking difference. Whereas Tirzepatide causes a dose-dependent decrease in weight over time, degludoc and other GLP-1R agonists cause weight gain[12].
It appears that the GIP agonism cause by Tirzepatide is what is responsible for the peptide’s long-term effects on weight. GIP appears to directly impact the insulin-sensitivity of adipocytes, which is likely the mechanism by which Tirzepatide impacts adiponectin levels. In short, Tirzepatide activates GIP receptors in fat cells, which then leads to an increase insulin sensitivity. This, in turn, leads to a reduction in adipose inflammation as well as an increase in adiponectin levels and the associated benefits. This isn’t the whole picture, however.
Research shows that GIP signaling in the central nervous system regulates hypothalamic feeding centers leading to decreased food intake and improved glucose handling. This, in turn, leads to decreased body weight[13]. Thus, it appears that Tirzepatide impacts weight via adiponectin signaling directly in adipose tissue and via CNS alterations that reduce hunger levels via GIPR signaling in the brain.Sumber:Sciencedirect
Tirzepatide dan hati
As noted, Tirzepatide alters adiponectin levels. Low adiponectin has been associated with atherosclerosis, obesity, and heart disease while increased adiponectin levels have been associated with decrease risk of all of these things. Research in humans with type 2 diabetes has shown that Tirzepatide improves lipoprotein biomarkers, lowering levels of triglycerides, apoC-III, and a handful of other lipoproteins[8]. Combined, these effects mean reduced risk of heart disease as a likely result of decreased adiposity. Research shows that increased adiponectin levels increase HDL levels while decreasing triglyceride levels, both of which are associated with lower risk of heart disease. The peptide hormone appears to go further though, reducing scavenger receptors in macrophages and increasing the levels of cholesterol efflux to greatly protect against atherosclerosis. Increases in adiponectin levels have been associated with improved nutrition, exercise, and the use of certain lipid-lowering medications[9]. It appears that Tirzepatide has similar beneficial effects.
Research shows that GLP-1 is important in both the direct regulation of cardiovascular risk factors such as hypertension, dyslipidemia, and obesity as well as in the indirect regulation of risk factors like inflammation and endothelial cell dysfunction[10]. The former effects are discussed above and below in relationship to adiponectin. The effects on inflammation and endothelial function, however, appear to be mediated more directly.
In the case of endothelial function, GLP-1 signaling has been shown to induce relaxation of blood vessels leading to decreased blood pressure and enhanced end organ perfusion. This effect appears to result from increased expression of eNOS, the enzyme that generates nitric oxide and induces vascular relaxation. Interestingly, these effects appear to be enhanced in the setting of preexisting cardiovasulcar disease and diabetes[10].
Of course, it is well known that inflammation is directly correlated with atherosclerosis. The details are still being worked out, but GLP-1 signaling appears to decrease inflammation via a handful of mechanisms including reduced NF-κB signaling, decreased MMP-9 activity, inhibited inflammatory cytokine synthesis, and decreases in inflammatory macrophage activity. What is more, these effects appear to last as long as three months after a single dose of a GLP-1R agonist like Tirzepatide[10]. Tirzepatide is undergoing a clinical trial to further evaluate its medium-term effects on individuals with heart failure[11].
Ringkasan Tirzepatide
Tirzepatide adalah turunan sintetis dari polipeptida penghambat lambung (GIP) yang memiliki fungsionalitas peptida-1 (GLP-1) seperti glukagon simultan juga. Kombinasi ini memungkinkan tirzepatida untuk menurunkan kadar glukosa darah, meningkatkan sensitivitas insulin, meningkatkan perasaan kenyang, dan mempercepat penurunan berat badan. Tirzepatide dikembangkan untuk melawan diabetes tipe 2, tetapi juga telah terbukti melindungi sistem kardiovaskular dan bertindak sebagai agen penurunan berat badan yang kuat.
Penulis artikel
Literatur di atas diteliti, diedit dan diselenggarakan oleh Dr. E. Logan, M.D. Dr. E. Logan memegang gelar doktor dariCase Western Reserve University School of Medicinedan seorang B.S. dalam biologi molekuler.
Penulis Jurnal Ilmiah
Kyle Sloopis a Research Advisor in the Endocrine Discovery Division of Lilly Research Laboratories at Eli Lilly and Company in Indianapolis. He received a B.Sc. in biology from Indiana University, a M.Sc. in biotechnology from Northwestern University, and the Ph.D. in molecular biology and biochemistry from Purdue University. Dr. Sloop’s research investigates molecular mechanisms that control glucose homeostasis, including insulin secretion and action, with a focus on novel therapeutic targets for metabolic disease. He leads interdisciplinary teams on early drug discovery effort, has formed alliance partnerships with external companies specialized in enabling technologies, and currently has established basic research collaborations with international investigators to explore mechanism of action studies for high value targets, including the areas of GPCR allosterism, ligand bias signaling, and protein-protein interaction. He previously served on the Research Affairs Committee of the Endocrine Society and as faculty for the Society’s Early Investigators Workshop and Early Career Forum.
Dr. Kyle Sloop is being referenced as one of the leading scientists involved in the research and development of Cardiogen. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between
Guru peptidadan dokter ini. Tujuan dari mengutip dokter adalah untuk mengakui, mengenali, dan menghargai penelitian lengkap dan upaya pengembangan yang dilakukan oleh para ilmuwan yang mempelajari peptida ini. Kyle Sloop terdaftar di[5]Dan[14]di bawah kutipan yang direferensikan.
Kutipan yang direferensikan
M. K. Thomaset Al., “Ganda GIP dan agonis reseptor GLP-1 Tirzepatide meningkatkan fungsi sel beta dan sensitivitas insulin pada diabetes tipe 2,” J. Clin. Endokrinol. Metab., Vol. 106, no. 2, hlm. 388–396, November 2020, doi: 10.1210/cloaM/DGAA863.
T. Min dan S. C. Bain, “Peran agonis reseptor Tirzepatide, Dual GIP dan GLP-1, dalam manajemen diabetes tipe2: uji klinis yang melampaui,” Diabetes Ther., Vol. 12, no. 1, hlm. 143–157, Januari 2021, doi: 10.1007/s13300-020-00981-0.
Frias, Juan Pablo, dkk. “Kemanjuran dan tolerabilitas tirzepatide, peptida insulinotropik yang bergantung pada glukosa dan agonis reseptor peptida-1 seperti glukagon pada pasien dengan diabetes tipe 2: studi 12 minggu, acak, double-blind, terkontrol plasebo untuk mengevaluasi regimen dosis-eskalasi yang berbeda. Diabetes, Obesitas dan Metabolisme, Vol. 22, no. 6, 11 Februari 2020, hlm. 938–946, 10.1111/dom.13979.
"Menghidupkan kembali sel beta pada diabetes tipe 2," Medscape. http://www.medscape.org/viewarticle/544820 (diakses 03 April 2022).
F. S. Willardet al., “Tirzepatide adalah agonis reseptor ganda dan GLP-1 yang tidak seimbang dan bias,” JCI Insight, vol. 5, tidak. 17, hlm. E140532, doi: 10.1172/jci.insight.140532.
M. L. Hartmanet AL., “Efek dari novel GIP Dual dan agonis reseptor GLP-1 Tirzepatide pada biomarker steatohepatitis nonalkoholik pada pasien dengan diabetes tipe 2,” Diabetes Care, vol. 43, no. 6, hlm. 1352–1355, Juni 2020, doi: 10.2337/dc19-1892.
Urva, Shweta, dkk. “Insulinotropik polipeptida insulinotropik yang bergantung pada glukosa dan glukagon-like peptide-1 (GLP-1) agonis yang mirip glukagon (GLP-1) secara transien menunda pengosongan lambung yang mirip dengan agonis reseptor GLP-1 yang bekerja secara selektif.” Diabetes, Obesitas dan Metabolisme, Vol. 22, no. 10, 13 Juli 2020, hlm. 1886–1891, 10.1111/dom.14110.
Wilson, Jonathan M., et al. “Insulinotropik peptida yang bergantung pada glukosa dan agonis reseptor peptida-1 seperti glukagon, tirzepatida, meningkatkan biomarker lipoprotein yang terkait dengan resistensi insulin dan risiko kardiovaskular pada pasien dengan diabetes tipe 2.” Diabetes, Obesitas dan Metabolisme, Vol. 22, no. 12, 15 September 2020, hlm. 2451–2459, 10.1111/dom.14174.
H. Yanai dan H. Yoshida, “Efek menguntungkan adiponektin pada metabolisme glukosa dan lipid dan perkembangan aterosklerotik: mekanisme dan perspektif,” Int. J. Mol. Sci., Vol. 20, tidak. 5, hlm. 1190, Maret 2019, doi: 10.3390/IJMS20051190.
M. Tate, A. Chong, E. Robinson, B. D. Green, dan D. J. Grieve, “Penargetan selektif pensinyalan peptida-1 seperti glukagon sebagai pendekatan terapi baru untuk penyakit kardiovaskular pada diabetes,” Br. J. Pharmacol., Vol. 172, no. 3, hlm. 721–736, Februari 2015, doi: 10.1111/bph.12943.
UCSD, “UCSD Obesity Trial: Sebuah Studi Tirzepatide (LY3298176) pada peserta dengan gagal jantung dengan fraksi dan obesitas ejeksi yang diawetkan (KTT).” https://clinicaltrials.ucsd.edu/trial/nct04847557 (diakses 03 April 2022).
B. Ludviket al., “Tirzepatide sekali-seminggu versus insulin degludec sekali sehari sebagai tambahan untuk metformin dengan atau tanpa inhibitor SGLT2 pada pasien dengan diabetes tipe 2 (SURPASS-3): label terbuka, label terbuka, kelompok paralel, uji coba fase 3,” Lancet Lond. Engl., Vol. 398, no. 10300, hlm. 583–598, 2021 Agustus, doi: 10.1016/s0140-6736 (21) 01443-4.
Q. Zhanget al., “Insulinotropik polipeptida (GIP) yang bergantung pada glukosa mengatur berat badan dan asupan makanan melalui pensinyalan CNS-GIPR,” Metab Sel., Vol. 33, tidak. 4, hlm. 833-844.E5, 2021 April, doi: 10.1016/j.cmet.2021.01.015.
Semua artikel dan informasi produk yang disediakan di situs web ini hanya untuk tujuan informasi dan pendidikan.Produk yang ditawarkan di situs web ini dilengkapi hanya untuk studi in-vitro. Studi in-vitro (Latin: dalam kaca) dilakukan di luar tubuh. Produk -produk ini bukan obat -obatan atau obat -obatan dan belum disetujui oleh FDA untuk mencegah, mengobati atau menyembuhkan kondisi medis, penyakit atau penyakit apa pun. Pengenalan tubuh dalam bentuk apa pun ke dalam manusia atau hewan dilarang secara ketat oleh hukum.
Peptidegurus adalah pemasok terkemuka peptida penelitian buatan Amerika, menawarkan produk berkualitas tinggi dengan harga kompetitif. Dengan fokus pada keunggulan dan layanan pelanggan, mereka memastikan proses pemesanan yang aman dan nyaman dengan pengiriman global.
